Skip to main content
. 2017 Feb 10;8(12):19923–19933. doi: 10.18632/oncotarget.15252

Figure 4. Random-effects Model of odds ratio (95%CI) of treatment discontinuation associated with dual anti-HER2 agents versus anti-HER2 monotherapy.

Figure 4